Supplementary IOL
Colin Kerr
Published: Saturday, April 1, 2017
Rayner has announced that a selection of models in their Sulcoflex range of pseudophakic supplementary IOLs have received Chinese Food and Drug Administration (CFDA) approval.
“After a four-year registration application – the longest in the history of Rayner – the CFDA has confirmed it’s approval of this selection of Sulcoflex IOLs. This innovation has been successfully implanted for 10 years and we are excited about launching it in a market as important as China,” said Rayner’s Commercial Director Cary Dawes.
“China is Rayner’s number one distributor market in terms of size and growth, so to add the Sulcoflex platform to our offering will open up even more growth opportunities,” he said.
www.rayner.com
Latest Articles
From Lab to Life: Corneal Repair Goes Cellular
Long-awaited cellular therapies for corneal endothelial disease enter the clinic.
Balancing Innovation and Safety
Ensuring access to advanced cell therapies amid regulatory overhaul.
With Eyes on Its Future, ESCRS Celebrates Its Past
Winter Meeting offers opportunities to experiment with new concepts and formats.
Best of ESCRS Winter Meeting 2024
Following the New Generation
EDOF IOLs an option for eyes with mild comorbidities, showing potential in mini-monovision strategies.
Refocus on Multifocals
Trifocal IOLs continue to improve as consensus grows regarding indications and contraindications.
Common Myths in Presbyopia Correction
Patient education key to satisfaction with refractive IOLs.
Reversible Multifocality
Two-lens combination offers low-risk spectacle independence for cataract patients and presbyopes.
Managing a Cataract Surgery Refractive Miss
Weighing the pros and cons of options for intraocular intervention.
Unleashing OCT’s Full Potential
Performance of newest tool for corneal evaluation meets or beats older standard technologies.